Passage Bio
PASG
99 hedge funds and large institutions have $278M invested in Passage Bio in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 22 reducing their positions, and 18 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 22
30% more call options, than puts
Call options by funds: $90K | Put options by funds: $69K
0.15% more ownership
Funds ownership: 3.89% → 4.04% (+0.15%)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 101 → 99 (-2)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
34% less capital invested
Capital invested by funds: $419M → $278M (-$142M)
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$13M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.4M |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$4.37M |
| 4 |
Morgan Stanley
New York
|
+$3.34M |
| 5 |
BlackRock
New York
|
+$3.05M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$19.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.37M |
| 4 |
JP Morgan Chase
New York
|
-$1.56M |
| 5 |
Bank of New York Mellon
New York
|
-$1.5M |
PASG Hedge Fund Activity: Q4 2021 in Review
99 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2021, worth a combined $278M — down 34% from $419M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PASG and 17 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 41 added.
The largest buyer was Woodline Partners, adding an estimated $13M. The largest seller was Fidelity Investments, cutting an estimated $31.4M.
- 99 institutional investors held Passage Bio (PASG) as of Q4 2021, down from 101 in Q3 2021.
- Funds reported $278M of Passage Bio stock for Q4 2021, down 34% quarter-over-quarter.
- 17 funds opened new Passage Bio positions in Q4 2021 and 18 closed out, a net change of -1 holder.
- The largest Passage Bio buyer in Q4 2021 was Woodline Partners, an estimated $13M added.
- The largest Passage Bio seller in Q4 2021 was Fidelity Investments, an estimated $31.4M sold.
Based on aggregated 13F filings for Q4 2021.